Kala Bio, Inc. (KALA)
2.33
+0.04
(+1.75%)
USD |
NASDAQ |
Jun 09, 16:00
2.33
0.00 (0.00%)
After-Hours: 17:40
Kala Bio SG&A Expense (Quarterly) : 1.741M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Acurx Pharmaceuticals, Inc. | 1.374M |
| ACADIA Pharmaceuticals, Inc. | 171.02M |
| Alnylam Pharmaceuticals, Inc. | 322.55M |
| Savara, Inc. | 15.57M |
| Vericel Corp. | 49.23M |